Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDA Approvals, Submissions Decline With New Review Goal Coming

Executive Summary

Is a rush of generic applications seeking the 10-month clock on the way?

You may also be interested in...



ANDA Approvals, Complete Responses Hit Record In FY 2016

FDA's Office of Generic Drugs completes its best year of the GDUFA era.

FDA Hiring Campaign Continues; Goal Is Addressing Pending ANDAs

GDUFA funding will bring 50 additional people to the Office of Pharmaceutical Quality for generic drug review purposes.

GDUFA II: ANDAs, Not Facilities Will Govern Revenue

Since applications comprise most of the workload, they will be the focus in the next generic drug user fee cycle.

Related Content

Topics

UsernamePublicRestriction

Register

PS118956

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel